首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   16745篇
  免费   556篇
  国内免费   586篇
耳鼻咽喉   129篇
儿科学   573篇
妇产科学   290篇
基础医学   1025篇
口腔科学   257篇
临床医学   1746篇
内科学   2386篇
皮肤病学   182篇
神经病学   436篇
特种医学   396篇
外国民族医学   16篇
外科学   1494篇
综合类   2657篇
预防医学   3161篇
眼科学   194篇
药学   1061篇
  78篇
中国医学   888篇
肿瘤学   918篇
  2024年   24篇
  2023年   274篇
  2022年   443篇
  2021年   521篇
  2020年   384篇
  2019年   77篇
  2018年   181篇
  2017年   137篇
  2016年   1060篇
  2015年   960篇
  2014年   756篇
  2013年   667篇
  2012年   1101篇
  2011年   1393篇
  2010年   343篇
  2009年   299篇
  2008年   916篇
  2007年   939篇
  2006年   894篇
  2005年   1004篇
  2004年   804篇
  2003年   794篇
  2002年   779篇
  2001年   830篇
  2000年   718篇
  1999年   446篇
  1998年   162篇
  1997年   38篇
  1996年   71篇
  1995年   93篇
  1994年   110篇
  1993年   59篇
  1992年   53篇
  1991年   41篇
  1990年   64篇
  1989年   44篇
  1988年   44篇
  1987年   50篇
  1986年   36篇
  1985年   42篇
  1984年   34篇
  1983年   40篇
  1982年   32篇
  1981年   18篇
  1980年   17篇
  1979年   19篇
  1978年   30篇
  1977年   5篇
  1959年   7篇
  1958年   4篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
目的 为了解闽东地区新生儿败血症临床表现、主要病原菌及其药敏情况。方法 本篇回顾性分析了54例2000年2月~2003年4月闽东医院儿科住院的血培养阳性的新生儿败血症患儿的临床表现、主要病原菌、药敏实验结果。结果主要临床表现:黄疸占48.1%,少哭、少动、少吃、反应差占46.3%,外周血象WBC<10 × 109/L占37.1%。金黄色葡萄球菌败血症26例(占48.1%)和表皮葡萄球菌16例(占29.6%)为主要致病菌。几乎全部对青霉素及红霉素耐药,对菌必治与先锋V敏感率>73.1%,尚未发现耐万古霉素的菌株。结论 新生儿出现黄疸、反应差等临床表现即使血白细胞不高也需考虑败血症的可能,治疗首选抗菌素为先锋V。  相似文献   
72.
儿童卵巢肿瘤国内、外文献报道颇少,恶性组的较大组报道,仅见La Vecehia(1983)收集英国国家癌症登记处1962~1978年间183例,国内偶有零星报道,本文收集1965~19R6年间资料较完整者110例分析如下。  相似文献   
73.
Synaptotagmin(Syt)constitutes a family of membrane-trafficking proteins,so far nearly 20 Syts have beendiscovered.Extensive work showed that synatotagmins were a potential Ca~(2+) sensor for regulated exocytosis.Thisstudy was to investigate the expression and location of synaptotagmin Ⅱ(Syt2)in RBL-2H3(RBL)and its role inregulating exocytosis of RBL.The expression of Syt2 in RBL was confirmed by Western blot.The recombinantexpression vector pEGFP-N1-Syt2 was constructed and transfected into RBL by electroporation,the stabletransfectant RBL-Syt2-S expressing fusion protein Syt2-EGFP were obtained and Syt2 was highly concentrated atplasma membrane with little detected in cytoplasm.To analyze the role of Syt2 during exocytosis of RBL,therelease of cathepsin D was assayed by immunoblotting.Compared with control,the release of cathepsin D byRBL-Syt2-S was markedly decreased.The results indicated that Syt2 played a negative regulation in exocytosis oflysosomes in RBL.Cellular & Molecular Immunology.2005;2(3):205-209.  相似文献   
74.
The authors studied the effect of zidovudine (ZDV) resistance mutation on virologic response to treatment with ZDV or stavudine (d4T) each in combination with lamivudine and indinavir. Viral genotyping was performed on plasma HIV-1 RNA at study entry and concerned 155 patients previously treated with ZDV, didanosine, or zalcitabine and enrolled in the NOVAVIR (Agence National de Recherche sur le SIDA [ANRS] 073) trial. Three virologic responses were investigated: early response (<50 copies/mL at week 24), late response (<500 copies/mL at week 80), and virologic failure (two HIV-1 RNA >5000 copies/mL). Patients were classified as resistant or susceptible to ZDV according to the ANRS algorithm. Plasma viral RNA from 123 of 155 patients had two or more ZDV resistance mutations. The number of ZDV resistance mutations was positively correlated with the duration of prior antiviral therapy (p <.001). At week 24, 74% and 77% of patients with virus classified as resistant were responders in the d4T and ZDV arm, respectively. Similar results were found at week 80. Virologic failure was reached in 7 of 24 patients with virus classified as susceptible and in 26 of 131 patients with resistant virus (p =.29). In the ZDV arm, patients classified as resistant had longer times to virologic failure than those classified as susceptible (p =.003). In conclusion, sustained virologic response despite presence of ZDV resistance mutations implies that these mutations do not preclude an early and durable response to treatment with a potent three-drug regimen in these patients. Patients susceptible to ZDV had lower median mean corpuscular volumes and lower random indinavir levels, suggesting that adherence was the main reason for failure.  相似文献   
75.
结直肠癌与人类乳头状瘤病毒(Human papilloma virus,HPV)感染有一定的关系,但由于检测方法、标本选择及样本数量不同,各研究结果之间差异很大。为进一步明确结直肠癌变与HPV16感染的关系,采用多聚酶链反应(Polymerase chain reaction,PCR)对82例原发性结直肠腺癌患者手术切除的新鲜癌及癌旁正常粘膜组织进行了前瞻性对照研究,检测了组织中HPV16E7DNA的表达并进行测序鉴定。结果显示,结直肠腺癌组织HPV16E7的表达阳性率(42/82)明显高于癌旁正常粘膜组织(4/82);直肠癌组织中HPV16E7的表达(64.10%)明显高于升结肠癌(18.18%),即癌灶部位距肛门越近,感染率越高;HPV16阳性率与Dukes分期相关,Dukes分期越晚感染率越高;与癌组织分化程度无相关性。结果提示结直肠癌的发生、发展可能与HPV16感染有关。  相似文献   
76.
The International Herpes Management Forum (IHMF) has published guidelines for the diagnosis and management of cytomegalovirus (CMV) infection and disease in solid organ (SOT) and haematopoietic stem cell transplant (HSCT) recipients. These recommendations have been updated to include, among others: (1) use of whole blood for the polymerase chain reaction (PCR) diagnosis of CMV infection; (2) CMV load measurements for prognostication and for monitoring response to anti-CMV therapy; (3) valganciclovir prophylaxis in CMV donor-positive/recipientnegative (D+/R-) SOT patients for prevention of CMV disease; (4) oral ganciclovir prophylaxis, in preference to aciclovir, to reduce incidence of CMV disease in SOT patients; (5) pre-emptive therapy with oral ganciclovir to reduce incidence of CMV disease and viraemia in liver transplant patients; (6) valaciclovir prophylaxis, in preference to high-dose oral aciclovir, to prevent CMV infection in allogeneic HSCT patients; and (7) foscarnet as an alternative to intravenous ganciclovir for pre-emptive treatment of CMV infection in allogeneic HSCT patients. New developments in the field requiring further research were highlighted, including: optimal frequency of CMV monitoring in CMV D+/R- SOT patients; optimal duration of prophylaxis for the prevention of late CMV disease; need for an acceptable viral threshold for initiation of pre-emptive therapy; and assessment of the clinical efficacy of valganciclovir for the treatment of CMV disease and as pre-emptive therapy in SOT and HSCT patients. This article presents supporting evidence for these recommendations and statements.  相似文献   
77.
78.
79.
Ithasbeenprovedthatanumberofdiseasesarerelatedwithabnormalityofbloodviscosityandcoagulationinclinicalresearch.Bloodhyperviscosityandhypercoagulationcauseandaccelearatethedevelopmentofcertaindiseases,deathrateofsomeofwhicharerisingwithyears.Lookingforawaytoreducebloodviscosityandrestrainfasterandstrongercoagulationbecomesasubjectdrawingmoreattention.Theproperseofthisresearchwastofindsuchaway.Intheblood,therearechargrdRBC,WBC,PLT,inorganicions,sothattheremustbesensitiveandcomplicatedresponse…  相似文献   
80.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号